Welichem announces substantial issuer bid

Welichem Biotech Inc. ("Welichem" or the "Company", TSX.V: WBI) announces that it is making a substantial issuer bid pursuant to which it will offer to purchase for cancellation up to 23,294,411 of its outstanding common shares ("Shares") at a purchase price of $0.85 per Share for an aggregate purchase price of up to $20 million (the "Offer"). The Offer is being made to provide its shareholders with an opportunity for liquidity, as trading on the TSX Venture Exchange has been historically low. The Offer will remain open for acceptance until 5:00 p.m. (Toronto time) on October 9, 2013.

The Offer will not be conditional on any minimum number of Shares being tendered to the Offer, but will be subject to other conditions customary for transactions of this nature, including receipt of all required regulatory approvals, including the TSX Venture Exchange.

Stellar Biotechnologies, Inc. Announces US $12,000,000 Private Placement

Stellar Biotechnologies, Inc. ("Stellar" or "the Company") (OTCQB: SBOTF) (TSX VENTURE: KLH) announces its intent to close a private placement of up to 11,428,572 units (the "Units") to raise gross proceeds of up to US$12,000,000 (the "Private Placement"). Each Unit will have a purchase price of US$1.05 and will consist of one common share in the capital of the Company and one-half of a transferable share purchase warrant (a "Warrant"). Each whole Warrant will entitle the holder to purchase one additional common share in the capital of the Company at a purchase price of US$1.35 for a period three years from the date of issuance of the Warrants.

XOMA Announces Pricing of $27.5 Million Offering of Common Stock

XOMA Corporation (XOMA), announced today the pricing of 7,596,685 shares of its common stock at a price to the public of $3.62 per share. In addition, XOMA has granted the underwriters a 30-day option to purchase up to an additional 1,139,502 shares of common stock on the same terms and conditions, solely to cover over-allotments, if any. The shares will be issued pursuant to a prospectus supplement filed as part of a shelf registration statement previously filed with the Securities and Exchange Commission (SEC) on Form S-3. XOMA anticipates its aggregate net proceeds from the offering will be approximately $25.5 million after deducting the underwriting discount and estimated offering expenses payable by XOMA. The offering is expected to close on or about August 23, 2013, subject to customary closing conditions.

Sirona Biochem Signs LOI With China's #1 Ranked Anti-Diabetic Company, Wanbang Pharma

Sirona Biochem Corp. (TSX VENTURE:SBM) (OTCQX:SRBCF) (ZSB.F) announced today the signing of a Letter of Intent whereby Sirona Biochem will provide an exclusive license to Wanbang Pharma to develop and commercialize Sirona's SGLT2 Inhibitor in the People's Republic of China (PRC). In exchange for this license, Sirona Biochem will receive upfront and milestone payments of up to US$9.5M upon successful achievement of development and regulatory milestones and then royalty payments for product sales in the PRC.

Under the terms of the LOI, Wanbang Pharma will assume responsibility for funding and leading all clinical studies required for Chinese Food and Drug Administration approval. Sirona Biochem will be provided all clinical study results to support new regulatory applications outside of PRC.